Colomycin is developed by The Leeds Teaching Hospitals NHS Trust.

What development phase is Colomycin in?

Colomycin is FDA-approved (marketed).

Last reviewed 2026-04-19 · How we verify

Colomycin

The Leeds Teaching Hospitals NHS Trust · FDA-approved active Small molecule

At a glance

Generic name	Colomycin
Sponsor	The Leeds Teaching Hospitals NHS Trust
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-calcoaceticus Complex (PHASE3)
Bacterial Load Guided Therapy for Severe Bronchiectasis Exacerbations (PHASE4)
Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive (NA)
The Effect of Colistin Inhalation on Ventilator Associated Pneumonia (PHASE2, PHASE3)
Antibiotic Nephrotoxicity in Adult Patients With Cystic Fibrosis (NA)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Colomycin CI brief — competitive landscape report
Colomycin updates RSS · CI watch RSS
The Leeds Teaching Hospitals NHS Trust portfolio CI